Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sacituzumab govitecan + mocaciclib
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Sacituzumab govitecan + mocaciclib (Q901) is an investigational combination therapy being evaluated for the treatment of advanced triple-negative breast cancer (TNBC). Sacituzumab govitecan is a TROP-2-directed antibody-drug conjugate (ADC) that utilizes a humanized IgG1 antibody to deliver SN-38, a potent topoisomerase I inhibitor, directly to tumor cells. Mocaciclib (Q901) is a highly selective small molecule inhibitor of Cyclin-Dependent Kinase 7 (CDK7). CDK7 plays a dual role in regulating the cell cycle (by activating other CDKs) and transcription (by phosphorylating the C-terminal domain of RNA polymerase II). The combination aims to leverage the cytotoxic effects of SN-38-induced DNA damage alongside the cell cycle arrest and transcriptional inhibition mediated by CDK7 blockade, potentially overcoming resistance in heavily pretreated TNBC patients.
- Brand names
- Trodelvy
- Other names
- Sacituzumab-Govitecan Plus Q901SG + Q901sacituzumab govitecan + Q901
02
Targets
CDK7TOP1 (DNA Topoisomerase I)TACSTD2 (Tumor-associated calcium signal transducer 2)
Beyond the preview
Go deeper on sacituzumab govitecan + mocaciclib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sacituzumab govitecan + mocaciclib.